Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document:
https://hdl.handle.net/2445/126909
Títol: | High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus |
Autor: | San Juan, Rafael Viedma, Esther Chaves, Fernando Lalueza, Antonio Fortún, Jesús Loza, Elena Pujol Rojo, Miquel Ardanuy Tisaire, María Carmen Morales, Isabel Cueto, Marina de Resino Foz, Elena Morales Cartagena, Alejandra Rico, Alicia Romero, María P. Orellana, María Ángeles López Medrano, Francisco Fernández Ruiz, Mario Aguado, José María |
Matèria: | Sang Malalties bacterianes Factors de risc en les malalties Efecte dels medicaments sobre els microorganismes Blood Bacterial diseases Risk factors in diseases Effect of drugs on microorganisms |
Data de publicació: | juny-2016 |
Publicat per: | Centers for Disease Control and Prevention |
Resum: | We investigated the prognostic role of high MICs for antistaphylococcal agents in patients with methicillin-sensitive Staphylococcus aureus catheter-related bloodstream infection (MSSA CRBSI). We prospectively reviewed 83 episodes from 5 centers in Spain during April 2011 June 2014 that had optimized clinical management and analyzed the relationship between E-test MICs for vancomycin, daptomycin, oxacillin, and linezolid and development of complicated bacteremia by using multivariate analysis. Complicated MSSA CRBSI occurred in 26 (31.3%) patients; MICs for vancomycin and daptomycin were higher in these patients (optimal cutoff values for predictive accuracy = 1.5 mu g/mL and 0.5 mu g/mL). High MICs for vancomycin (hazard ratio 2.4, 95% CI 1.2-5.5) and daptomycin (hazard ratio 2.4, 95% CI 1.1-5.9) were independent risk factors for development of complicated MSSA CRBSI. Our data suggest that patients with MSSA CRBSI caused by strains that have high MICs for vancomycin or daptomycin are at increased risk for complications. |
Nota: | Reproducció del document publicat a: https://doi.org/10.3201/eid2206.151709 |
És part de: | Emerging Infectious Diseases, 2016, vol. 22, num. 6, p. 1057-1066 |
URI: | https://hdl.handle.net/2445/126909 |
Recurs relacionat: | https://doi.org/10.3201/eid2206.151709 |
ISSN: | 1080-6040 |
Apareix en les col·leccions: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Fitxers d'aquest document:
Fitxer | Descripció | Dimensions | Format | |
---|---|---|---|---|
662472.pdf | 1.55 MB | Adobe PDF | Mostrar/Obrir |
Aquest document té tots els drets reservats